| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
12,673 |
10,818 |
$5.34M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
16,142 |
14,317 |
$5.25M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,262 |
3,744 |
$2.77M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,441 |
1,286 |
$1.34M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,305 |
1,190 |
$700K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,656 |
2,431 |
$632K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,684 |
1,543 |
$274K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
189 |
173 |
$224K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,141 |
1,133 |
$120K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,328 |
2,058 |
$53K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
76 |
74 |
$32K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
828 |
697 |
$30K |
| 71046 |
Radiologic examination, chest; 2 views |
2,651 |
2,528 |
$28K |
| 73130 |
|
235 |
209 |
$6K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
95 |
92 |
$6K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,651 |
6,922 |
$6K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
232 |
213 |
$6K |
| 73562 |
|
478 |
413 |
$5K |
| 73630 |
|
430 |
389 |
$4K |
| A9270 |
Non-covered item or service |
8,146 |
6,389 |
$4K |
| 73610 |
|
318 |
282 |
$3K |
| 76830 |
Ultrasound, transvaginal |
85 |
81 |
$3K |
| 73030 |
|
242 |
216 |
$3K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
4,746 |
4,050 |
$3K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,463 |
2,930 |
$3K |
| 71045 |
Radiologic examination, chest; single view |
5,387 |
4,611 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,922 |
3,446 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,358 |
1,627 |
$1K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
14,529 |
11,447 |
$1K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,689 |
4,853 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,878 |
3,991 |
$861.74 |
| 80053 |
Comprehensive metabolic panel |
289 |
195 |
$689.80 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
14,184 |
11,236 |
$664.12 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,042 |
1,757 |
$530.35 |
| 76641 |
|
15 |
12 |
$513.74 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,416 |
1,287 |
$387.13 |
| 73110 |
|
47 |
43 |
$371.53 |
| 80076 |
|
7,954 |
6,749 |
$363.37 |
| 84443 |
Thyroid stimulating hormone (TSH) |
640 |
570 |
$293.75 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,545 |
1,402 |
$272.77 |
| 76642 |
|
13 |
12 |
$258.63 |
| 84484 |
|
6,144 |
4,212 |
$250.04 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,326 |
1,151 |
$233.42 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,934 |
1,879 |
$219.32 |
| 83690 |
|
4,658 |
4,000 |
$212.11 |
| 90715 |
|
749 |
716 |
$181.28 |
| 82550 |
|
1,393 |
1,014 |
$178.28 |
| 87186 |
|
729 |
565 |
$156.89 |
| 72100 |
|
15 |
14 |
$137.21 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,940 |
2,247 |
$133.07 |
| 81001 |
|
4,295 |
3,862 |
$99.89 |
| 73080 |
|
15 |
12 |
$84.33 |
| 83880 |
|
1,642 |
1,414 |
$69.85 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
983 |
830 |
$57.32 |
| 87040 |
|
2,527 |
1,172 |
$55.53 |
| 83735 |
|
2,569 |
1,748 |
$54.36 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,289 |
2,679 |
$54.24 |
| 81025 |
|
2,442 |
2,245 |
$53.88 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,120 |
983 |
$49.36 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,896 |
1,950 |
$47.06 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
639 |
606 |
$45.56 |
| 83605 |
|
2,681 |
1,879 |
$43.18 |
| 81000 |
|
2,704 |
2,354 |
$42.97 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,725 |
3,229 |
$42.01 |
| 85610 |
|
1,006 |
873 |
$31.50 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,984 |
1,721 |
$18.79 |
| 96376 |
|
1,349 |
1,048 |
$17.59 |
| 36415 |
Collection of venous blood by venipuncture |
5,651 |
4,327 |
$13.75 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
707 |
678 |
$8.92 |
| 87081 |
|
108 |
103 |
$8.15 |
| 87088 |
|
491 |
431 |
$6.98 |
| 96160 |
|
70 |
40 |
$6.10 |
| 84439 |
|
491 |
426 |
$5.77 |
| J2060 |
Injection, lorazepam, 2 mg |
296 |
196 |
$1.42 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
808 |
686 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
411 |
302 |
$0.00 |
| 84295 |
|
26 |
22 |
$0.00 |
| 80061 |
Lipid panel |
47 |
41 |
$0.00 |
| 84100 |
|
511 |
259 |
$0.00 |
| 29125 |
|
55 |
53 |
$0.00 |
| A4649 |
Surgical supply; miscellaneous |
13 |
13 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,970 |
1,692 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
529 |
411 |
$0.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
19 |
14 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
151 |
124 |
$0.00 |
| 96367 |
|
136 |
107 |
$0.00 |
| 82565 |
|
19 |
18 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
53 |
51 |
$0.00 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
70 |
65 |
$0.00 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
61 |
59 |
$0.00 |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
39 |
38 |
$0.00 |
| 84702 |
|
17 |
14 |
$0.00 |
| 94664 |
|
50 |
36 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
47 |
45 |
$0.00 |
| 83721 |
|
15 |
13 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
34 |
32 |
$0.00 |
| 82947 |
|
19 |
18 |
$0.00 |
| 93976 |
|
14 |
13 |
$0.00 |
| 10060 |
|
13 |
13 |
$0.00 |
| 86900 |
|
12 |
12 |
$0.00 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
592 |
586 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
549 |
461 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
53 |
51 |
$0.00 |
| 85730 |
|
361 |
331 |
$0.00 |
| 84703 |
|
842 |
745 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
537 |
393 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
207 |
175 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
146 |
136 |
$0.00 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
61 |
59 |
$0.00 |
| J3490 |
Unclassified drugs |
115 |
92 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
400 |
286 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
211 |
199 |
$0.00 |
| 85379 |
|
180 |
174 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
78 |
38 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
194 |
160 |
$0.00 |
| 82435 |
|
26 |
22 |
$0.00 |
| 12001 |
|
39 |
38 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
22 |
12 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
15 |
12 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
22 |
13 |
$0.00 |
| 84132 |
|
26 |
22 |
$0.00 |
| 86901 |
|
12 |
12 |
$0.00 |
| 84480 |
|
31 |
27 |
$0.00 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
14 |
13 |
$0.00 |
| 82330 |
|
20 |
18 |
$0.00 |
| 82803 |
|
17 |
12 |
$0.00 |